SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one ...
CARSON CITY, Nev., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of ...
CARSON CITY, Nev., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological ...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate ...
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing ...
-Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone- -Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON ...
Presenter: Joseph M. Palumbo, MD, Executive Vice President, Head of Research & Development and Chief Medical Officer, BioVie Inc. SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, ...
CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results